معرفی
Benjamin A. Howell, MD, MPH, MHS is an Assistant Professor of Medicine in the Section of General Internal Medicine at Yale School of Medicine. He holds additional faculty appointments in the Yale Program in Addiction Medicine and the SEICHE Center for Health and Justice, and is a member of the Janeway Society for physician-scientist development.
- Undergraduate: Columbia University
- MD: University of California, San Francisco
- MPH: UC Berkeley School of Public Health
- Residency & Chief Residency: Yale-New Haven Hospital (Internal Medicine-Primary Care)
- Post-doctoral Fellowship: National Clinician Scholars Program at Yale
Dr. Howell's research program focuses on addressing social and structural determinants of health to improve outcomes for justice-involved populations. His expertise spans health services research, addiction medicine, and criminal justice health, with particular emphasis on the opioid epidemic, overdose prevention, and health disparities among incarcerated and recently released individuals. He employs both quantitative and conceptual frameworks to examine how criminal legal involvement affects health outcomes and healthcare access.
His research portfolio reveals a clear trajectory examining the intersection of criminal justice involvement and health outcomes. Key themes include post-release mortality risks, medication-assisted treatment effectiveness, health insurance coverage disparities, and the impact of stigma on healthcare access for justice-involved populations. His work bridges clinical medicine, public health, and policy to develop evidence-based interventions for vulnerable populations.
- Addiction Medicine certification (American Board of Preventive Medicine, 2022)
- ORCID: 0000-0001-6938-8347
- Key collaborators: David Fiellin, Robert Heimer, Anne Black, Gail D'Onofrio, Lauretta Grau
Dr. Howell actively contributes to clinical care, research, and policy discussions surrounding addiction treatment in justice settings. His recent work has informed harm reduction strategies including naloxone distribution programs and expanded access to medications for opioid use disorder in correctional and community settings following release.